Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Penumbra, Inc. (PEN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that together outline Penumbra’s financial condition, major corporate events and obligations as a NYSE-listed issuer.
Among the most significant recent filings is a Form 8-K dated January 15, 2026, in which Penumbra reports entry into an Agreement and Plan of Merger with Boston Scientific Corporation and a Boston Scientific subsidiary. The filing describes the structure of the merger consideration, the mix of cash and Boston Scientific common stock, and the conditions required for closing. It also states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time.
Other Form 8-K filings highlighted here include results of operations and financial condition for specific quarters, where Penumbra furnishes earnings press releases as exhibits. These filings discuss revenue growth, gross margin, operating margin and the use of non-GAAP measures such as constant currency revenue, non-GAAP income from operations and adjusted EBITDA. The company explains how these non-GAAP metrics are calculated and why management considers them useful for assessing underlying business performance.
Additional 8-Ks address corporate governance and leadership changes, such as the appointment of a new company president and related compensation arrangements. These filings provide detail on board and executive decisions, equity awards and related person transactions, all within the framework of SEC disclosure requirements.
Through this page, users can follow Penumbra’s formal reporting on material events, financial results and the proposed merger with Boston Scientific. Stock Titan’s platform associates each filing with AI-powered summaries designed to explain the core points of lengthy documents, helping readers quickly understand items such as merger terms, earnings highlights, and key governance changes without having to parse every line of the underlying text.
For deeper research, investors can review the full text of Penumbra’s 10-K and 10-Q reports via the SEC’s EDGAR system, while using the summaries and context on this page as a guide to the most important disclosures affecting PEN and its anticipated transition to a wholly owned subsidiary of Boston Scientific.
Boston Scientific used its Q4 2025 call to highlight strong growth and the pending acquisition of Penumbra. The Cardiovascular segment grew 16% operationally and organically in the quarter and 21% organic for the full year, reflecting strength in fast-growing markets.
As of December 31, 2025, the company reported cash on hand of $1.965 billion and a gross debt leverage ratio of 1.9x. All three major rating agencies affirmed its single A minus equivalent credit rating, and Fitch raised its outlook from stable to positive.
Management closed the acquisition of Nalu Medical and announced deals for Valencia Technologies and Penumbra, expanding into urology and neurovascular/mechanical thrombectomy adjacencies. The CEO reaffirmed long-range goals for 10%+ organic revenue growth from 2026–2028, about 150 bps margin expansion, and strong double-digit EPS growth, while cautioning that these are forward-looking statements subject to significant risks.
Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at $14.5 billion. The company plans to fund about 73% of the deal in cash and 27% in stock, and expects the acquisition to close this year, subject to regulatory approvals and other conditions.
The transaction is designed to expand Boston Scientific’s cardiovascular portfolio and re-establish a strong neurovascular business, adding devices that treat stroke-causing blood clots in the brain and pulmonary embolism clots in the lungs. Penumbra expects roughly $1.4 billion of revenue in 2025, growing more than 17% over 2024. Boston Scientific anticipates the deal will slightly dilute profits in the first full year after closing, become neutral to slightly beneficial in the second year, and more beneficial thereafter.
Penumbra Inc.'s president, Shruthi Narayan, reported a routine tax‑related share withholding. On January 15, 2026, the issuer withheld 286 shares of common stock at $350.49 per share to cover tax obligations arising from the vesting of restricted stock units granted to her. Following this transaction, Narayan beneficially owns 26,317 shares of Penumbra common stock, held directly. This reflects an administrative adjustment tied to equity compensation rather than an open‑market sale.
Penumbra, Inc. has entered into a definitive agreement to be acquired by Boston Scientific Corporation, with the transaction expected to close in 2026, subject to customary conditions and approvals. Company leaders tell customers, distributors, suppliers and clinical study partners that Penumbra and Boston Scientific will operate independently until closing and that Penumbra’s products, contracts, commitments and clinical trials are expected to continue without change during this period. The messages emphasize ongoing focus on product excellence, innovation and global patient access. Investors are told that Boston Scientific will file a Form S-4 registration statement containing a joint proxy statement/prospectus, and that stockholders should carefully read those materials when available, as well as the detailed risk factors and forward-looking statement disclosures related to the proposed merger.
Boston Scientific plans to acquire Penumbra for $374 per share in a cash‑and‑stock deal valuing Penumbra at $15 billion. The consideration mix is about $11 billion in cash and $4 billion in Boston Scientific stock, with roughly 41 million new Boston Scientific shares issued, and closing targeted in 2026 subject to customary conditions.
Penumbra expects strong 2025 results, with preliminary Q4 2025 revenue growth of 21.4%–22% and full‑year revenue of about $1.4 billion, up roughly 17.3%–17.5%. Boston Scientific highlights Penumbra’s presence in high‑growth mechanical thrombectomy and neurovascular markets and plans to run Penumbra largely as a standalone business within its cardiovascular group while leveraging its global commercial and manufacturing footprint.
Financially, Boston Scientific projects the deal will be slightly dilutive to adjusted EPS in the first full year post‑close by $0.06–$0.08, turning slightly accretive in year two and increasingly accretive after achieving over $200 million of operating income impact from revenue synergies and cost efficiencies in year three. Management reiterates its goals for double‑digit EPS growth and long‑term margin expansion over 2026–2028.
Boston Scientific agreed to acquire Penumbra, Inc. through a merger where each Penumbra share will be converted, at the holder’s election and subject to proration, into either $374.00 in cash or 3.8721 Boston Scientific shares. Overall, 73.26% of Penumbra shares are expected to receive cash and 26.74% stock, with Penumbra becoming a wholly owned subsidiary of Boston Scientific if the deal closes. Completion depends on Penumbra stockholder approval, required regulatory clearances (including antitrust reviews), effectiveness of a Form S-4, and New York Stock Exchange listing of the new Boston Scientific shares, along with other customary conditions. The agreement includes a $525 million termination fee payable by Penumbra in certain competing-deal scenarios and a $900 million reverse termination fee payable by Boston Scientific if specified regulatory conditions are not met despite other closing conditions being satisfied.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation. Penumbra stockholders, including employees, are expected to receive $374 per share of Penumbra common stock in a mix of cash and Boston Scientific stock.
The transaction is expected to close in 2026, subject to Penumbra stockholder approval, required regulatory approvals and other customary closing conditions. After closing, Penumbra will become a standalone group within Boston Scientific, and Penumbra’s CEO is expected to join the Boston Scientific board.
Penumbra tells employees there are no immediate changes to day-to-day roles or reporting. Unvested restricted stock units are expected to vest at closing and convert into the same cash/stock mix, and existing employee stock purchase plans will continue through the current purchase period.
Boston Scientific Corporation has executed a definitive agreement to acquire Penumbra, Inc., with the transaction subject to specified terms and closing conditions in the merger agreement. The companies issued a joint press release and Boston Scientific scheduled a same-day conference call and posted an investor presentation to explain the proposed acquisition and its expected impact.
The report emphasizes that many statements about the transaction, its benefits, timing, integration, and future financial and business performance are forward-looking and subject to numerous economic, regulatory, operational, and integration risks, including required regulatory approvals and the possibility the transaction may be delayed or not close. Boston Scientific will file a Form S-4 with a joint proxy statement/prospectus so Penumbra stockholders can review detailed terms before voting.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation in a cash-and-stock merger, after which Penumbra will become a wholly owned subsidiary and its shares will be delisted from the NYSE. At closing, each Penumbra common share will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to proration so that approximately 73.26% of shares receive cash and 26.74% receive stock. The deal requires approval by Penumbra stockholders, antitrust clearances in the U.S. and other jurisdictions, an effective Form S-4 for Boston Scientific shares, and NYSE listing approval for those shares. The merger agreement includes a $525 million termination fee payable by Penumbra in certain circumstances and a $900 million reverse termination fee payable by Boston Scientific if antitrust-related conditions are not met despite other conditions being satisfied.